NLS Pharmaceutics Competitors and Similar CompaniesClear all
NLS Pharmaceutics's competitors and similar companies include ACADIA Pharmaceuticals, Supernus Pharmaceuticals, Alector and Stalicla.
 NLS Pharmaceutics NLS Pharmaceutics is a biopharmaceutical company engaged in drug discovery for central nervous system disorders. |  ACADIA Pharmaceuticals ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Alector Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases. |  Stalicla Stalicla is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders. | |
Founding Date | Founding Date 2019 | Founding Date 1993 | Founding Date 2005 | Founding Date 2013 | Founding Date 2017 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Stans, CH HQ | Locations San Diego, US HQ Princeton, US | Locations Rockville, US HQ | Locations San Francisco, US HQ | Locations Genève, CH HQ |
Employees | Employees 6 | Employees 513 | Employees 6527% increase | Employees 2382% decrease | Employees 264% increase |
Valuation ($) | Valuation ($) 10.2 m | Valuation ($) 2.4 b | Valuation ($) 1.9 b | Valuation ($) 495.3 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.1b (FY, 2025) | Revenue (est.) $719m (FY, 2025) | Revenue (est.) $21m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $89m (FY, 2025) | Cost of goods $74.6m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $2.5m (FY, 2024) | Gross profit $982.5m (FY, 2025) | Gross profit $644.4m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($2m) (FY, 2024) | Net income $391m (FY, 2025) | Net income ($38.6m) (FY, 2025) | Net income ($142.9m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 770.8m | Total funding raised $ 69.5m | Total funding raised $ 194.5m | Total funding raised $ 18.2m |
For sources of this data, please see the company profile
View Company Profiles
ACADIA Pharmaceuticals
HQ
San Diego, US
Employees
513
ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders.
View companySupernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View companyAlector
HQ
San Francisco, US
Employees
238↓ 2% decrease
Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases.
View companyStalicla
HQ
Genève, CH
Employees
26↑ 4% increase
Stalicla is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders.
View company